Vaderis Therapeutics Secures $152 Million in Latest Series B Funding Round

Vaderis Therapeutics secured $152 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Vaderis Therapeutics Raises $152 million in Funding

Switzerland: Vaderis Therapeutics closes US$152m Series B financing and initiates global Phase 3 clinical study. [.] The additional capital will enable Alchemab to advance ATLX-2847, a wholly-owned program for muscle atrophy derived from the platform, into clinical development.

Investors Behind the Funding

The round was backed by SR One. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Vaderis Therapeutics operates in Healthcare & Life Sciences. Vaderis Therapeutics's financing adds to recent private-market activity.

Strategic Use of Funds

develop innovative cancer treatments

Looking Ahead

Switzerland: Vaderis Therapeutics closes US$152m Series B financing and initiates global Phase 3 clinical study

Source reference: original announcement/article.